Gene · 1737
Papers2,650
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 2,650
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Electric-Field-Driven Ferredoxin 1-Independent Cuproptosis Induction Overcomes Therapy-Induced Resistance in Glioblastoma. | ACS Nano | 2026 | 42411583 | PubTator, text mining | PubMed |
| Environmental shaping of tolerance failure in autoimmune liver diseases: a phenotype-specific framework with primary biliary cholangitis as the strongest model. | J Transl Autoimmun | 2026 | 42403425 | PubTator, text mining | PubMed |
| Novel Biomarker for Antimitochondrial Antibodies in Systemic Sclerosis Patients. | J Immunol Res | 2026 | 42402832 | PubTator, text mining | PubMed |
| HPD is a copper-binding protein that interacts with DLAT to promote colorectal cancer cuproptosis under copper stress. | Cell Rep | 2026 | 42391001 | PubTator, text mining | PubMed |
| Cuproptosis and prostate cancer: from molecular mechanisms and microenvironment remodeling to precision therapy. | Front Oncol | 2026 | 42388635 | PubTator, text mining | PubMed |
| Analysis of end-stage renal disease mediated by cuproptosis-related genes. | Clin Nephrol | 2026 | 42383521 | PubTator, text mining | PubMed |
| NIR-II Light-Triggered Electron Flow Initiates Cuproptosis-Centered Thermoelectric-Immunotherapy for Breast Cancer. | Adv Sci (Weinh) | 2026 | 42378639 | PubTator, text mining | PubMed |
| Syringin disrupts the DLAT/MYC axis to dampen TAM polarization and suppress hepatocellular carcinoma progression. | Acta Pharm Sin B | 2026 | 42368569 | PubTator, text mining | PubMed |
| A TIGIT nanotrapping-guided STING-activatable immunometabolic strategy overcomes innate immune silence and T cell exhaustion in breast cancer. | J Control Release | 2026 | 42314987 | PubTator, text mining | PubMed |
| Mutant KRAS-driven selective mRNA translation reveals mechanisms and therapeutic vulnerabilities in cancer. | Cell Rep | 2026 | 42284146 | PubTator, text mining | PubMed |
| Relationships between immune cells, blood metabolites, and intrahepatic cholangiocarcinoma: a Mendelian randomization study with experimental validation. | Front Cell Dev Biol | 2026 | 42255475 | PubTator, text mining | PubMed |
| Hyaluronic acid-camouflaged dendritic silica nanoparticles enable targeted cuproptosis and photothermal therapy for lung cancer. | Colloids Surf B Biointerfaces | 2026 | 42247956 | PubTator, text mining | PubMed |
| Native mass spectrometry reveals DltA catalysis, DltC loading, and inhibition in the d-alanylation pathway. | RSC Adv | 2026 | 42245989 | PubTator, text mining | PubMed |
| G protein-coupled receptor 87 promotes lung adenocarcinoma progression and metastasis via a histone lactylation-driven glycolytic feed-forward circuit. | Free Radic Biol Med | 2026 | 42229819 | PubTator, text mining | PubMed |
| An autoantibody signature targeting cuproptosis-related proteins for non-small cell lung cancer detection and prognosis. | PeerJ | 2026 | 42222481 | PubTator, text mining | PubMed |
| pH-Responsive Bovine Serum Albumin Nanoparticles Encapsulating Doxorubicin-Based Complexes Induce Cuproptosis in Lung Cancer Cells. | Pharmaceutics | 2026 | 42198219 | PubTator, text mining | PubMed |
| The role of cuproptosis in osteoporosis: Molecular mechanisms and cell-specific regulation in bone metabolic imbalance. | Tissue Cell | 2026 | 42176681 | PubTator, text mining | PubMed |
| IGF2BP2 promotes cuproptosis of cardiomyocytes through m6A modification of MAP2K1 in sepsis-induced myocardial injury. | Cell Immunol | 2026 | 42167092 | PubTator, text mining | PubMed |
| CaO2-Powered Nanomotors with Enhanced Cellular Uptake and Lysosomal Escape for Cuproptosis and Reactive Oxygen Species-Mediated Synergistic Cancer Therapy. | ACS Appl Mater Interfaces | 2026 | 42126988 | PubTator, text mining | PubMed |
| Orchestrating mitochondrial catastrophe: Mechanistic insights and therapeutic frontiers of cuproptosis in precision pharmacology. | Curr Opin Pharmacol | 2026 | 42114175 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1737/papers?page=3